CD33 and acute myeloid leukemia: In a small clinical trial using CD33 CAR T-cells to treat one patient with refractory AML, CD33+ blast cells were decreased at two weeks, but had returned to high numbers by week 9 after treatment, accompanied by undesirable side effects [22].